Tango Therapeutics, Inc. Revenue
Tango Therapeutics, Inc. (TNGX) reported Revenue of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement
us-gaap:Revenues · last filed 2026-08-11
- Tango Therapeutics, Inc. revenues for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- Tango Therapeutics, Inc. revenues for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- Tango Therapeutics, Inc. revenues for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- Tango Therapeutics, Inc. revenues for the quarter ending 2025-09-30 was $53.81M, a 363.61% increase year-over-year.
- Tango Therapeutics, Inc. revenues for fiscal 2025 was $62.38M, a 48.29% increase from fiscal 2024.
- Tango Therapeutics, Inc. revenues for fiscal 2024 was $42.07M, a 15.17% increase from fiscal 2023.
- Tango Therapeutics, Inc. revenues for fiscal 2023 was $36.53M, a 46.93% increase from fiscal 2022.
- Tango Therapeutics, Inc. revenues for fiscal 2022 was $24.86M, a 32.89% decline from fiscal 2021.
| Period end | Revenues 3 month | Revenues 6 month | Revenues 9 month | Revenues 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-11 | $0.00 10-Q · filed 2026-08-11 | $0.00 derived: sum of 3 quarters · filed 2026-08-11 | $53.81M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-13 | $0.00 derived: sum of 2 quarters · filed 2026-05-13 | $53.81M derived: sum of 3 quarters · filed 2026-05-13 | $56.99M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $53.81M derived: sum of 2 quarters · filed 2026-03-05 | $56.99M derived: sum of 3 quarters · filed 2026-08-11 | $62.38M 10-K · filed 2026-03-05 |
| 2025-09-30 | $53.81M 10-Q · filed 2025-11-04 | $56.99M derived: sum of 2 quarters · filed 2026-08-11 | $62.38M 10-Q · filed 2025-11-04 | $66.50M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $3.18M 10-Q · filed 2026-08-11 | $8.57M 10-Q · filed 2026-08-11 | $12.69M derived: sum of 3 quarters · filed 2026-08-11 | $24.30M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $5.39M 10-Q · filed 2026-05-13 | $9.51M derived: sum of 2 quarters · filed 2026-05-13 | $21.12M derived: sum of 3 quarters · filed 2026-05-13 | $40.99M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $4.12M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $15.72M derived: sum of 2 quarters · filed 2026-03-05 | $35.60M derived: sum of 3 quarters · filed 2026-03-05 | $42.07M 10-K · filed 2026-03-05 |
| 2024-09-30 | $11.61M 10-Q · filed 2025-11-04 | $31.48M derived: sum of 2 quarters · filed 2025-11-04 | $37.95M 10-Q · filed 2025-11-04 | $43.38M derived: sum of 4 quarters · filed 2026-03-05 |
| 2024-06-30 | $19.88M 10-Q · filed 2025-08-05 | $26.35M 10-Q · filed 2025-08-05 | $31.78M derived: sum of 3 quarters · filed 2026-03-05 | $42.51M derived: sum of 4 quarters · filed 2026-03-05 |
| 2024-03-31 | $6.47M 10-Q · filed 2025-05-12 | $11.90M derived: sum of 2 quarters · filed 2026-03-05 | $22.63M derived: sum of 3 quarters · filed 2026-03-05 | $37.23M derived: sum of 4 quarters · filed 2026-03-05 |
| 2023-12-31 | $5.43M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $16.16M derived: sum of 2 quarters · filed 2026-03-05 | $30.76M derived: sum of 3 quarters · filed 2026-03-05 | $36.53M 10-K · filed 2026-03-05 |
| 2023-09-30 | $10.73M 10-Q · filed 2024-11-06 | $25.33M derived: sum of 2 quarters · filed 2024-11-06 | $31.10M 10-Q · filed 2024-11-06 | $37.51M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $14.60M 10-Q · filed 2024-08-07 | $20.36M 10-Q · filed 2024-08-07 | $26.77M derived: sum of 3 quarters · filed 2025-02-27 | $33.70M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $5.77M 10-Q · filed 2024-05-08 | $12.18M derived: sum of 2 quarters · filed 2025-02-27 | $19.10M derived: sum of 3 quarters · filed 2025-02-27 | $24.87M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $6.41M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $13.33M derived: sum of 2 quarters · filed 2025-02-27 | $19.10M derived: sum of 3 quarters · filed 2025-02-27 | $24.86M 10-K · filed 2025-02-27 |
| 2022-09-30 | $6.92M 10-Q · filed 2023-11-08 | $12.69M derived: sum of 2 quarters · filed 2023-11-08 | $18.45M 10-Q · filed 2023-11-08 | $24.16M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $5.77M 10-Q · filed 2023-08-07 | $11.53M 10-Q · filed 2023-08-07 | $17.25M derived: sum of 3 quarters · filed 2023-08-07 | $24.03M derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | $5.76M 10-Q · filed 2023-05-09 | $11.47M derived: sum of 2 quarters · filed 2023-05-09 | $18.26M derived: sum of 3 quarters · filed 2023-05-09 | $36.41M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $5.72M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-27 | $12.50M derived: sum of 2 quarters · filed 2023-03-27 | $30.66M derived: sum of 3 quarters · filed 2023-03-27 | $37.04M 10-K · filed 2023-03-27 |
| 2021-09-30 | $6.79M 10-Q · filed 2022-11-10 | $24.94M derived: sum of 2 quarters · filed 2022-11-10 | $31.33M 10-Q · filed 2022-11-10 | $40.47M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $18.15M 10-Q · filed 2022-08-10 | $24.54M 10-Q · filed 2022-08-10 | $33.68M derived: sum of 3 quarters · filed 2022-08-10 | $22.42M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $6.39M 10-Q · filed 2022-05-11 | $15.53M derived: sum of 2 quarters · filed 2022-05-11 | $4.27M derived: sum of 3 quarters · filed 2022-05-11 | |
| 2020-12-31 | $9.14M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | -$2.12M derived: sum of 2 quarters · filed 2022-03-28 | $7.66M 10-K · filed 2022-03-28 | |
| 2020-09-30 | -$11.26M 10-Q · filed 2021-11-09 | -$1.49M 10-Q · filed 2021-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |